Discount Agreements for Pharmaceutical Products
Notice title: Open-House-Rabattverträge 2026-14
Discount agreements: Conclusion of discount agreements according to § 130a para. 8 SGB V for the active ingredients, active ingredient combinations, dosage forms, strengths, or finished medicinal products specified in each lot. The procedure includes the following active ingredients and products: Abiraterone (90 units), Adapalen/Benzoyl peroxide, Aliskiren (150 mg: N3), Bexarotene, Calcipotriol (CRE: N3), Clonidine (0.065 mg: N3), Diltiazem, Eletriptan, Eltrombopag (solid oral dosage form: excluding severe aplastic anemia indication), Eltrombopag (solid oral dosage form: including severe aplastic anemia indication), Ezetimibe/Atorvastatin (88 units, 90 units), Iodide (N3: 0.1 mg, 0.2 mg), Nitisinone (solid oral dosage form), Pazopanib, Prednisone (TAB, excluding 10 mg).
Never miss a tender again
We send you 3 current matches that fit your company.
Tender documents
- Portal — LOT-0001NON-RESTRICTED-DOCUMENT
- TED HTML — 567284-2026HTML
- TED PDF — 567284-2026PDF
- TED XML — 567284-2026XML
Unlock documents for free
Enter your email address. If you confirm, we will also send you 3 similar tenders.
Lots (15)
- LOT-0001Abirateron (90 St.)
- LOT-0002Adapalen/Benzoylperoxid
- LOT-0003Aliskiren (150 mg: N3)
- LOT-0004Bexaroten
- LOT-0005Calcipotriol (CRE: N3)
- LOT-0006Clonidin (0,065 mg: N3)
- LOT-0007Diltiazem
- LOT-0008Eletriptan (N2)
- LOT-0009Eltrombopag (feste orale DRF: exkl. der Indikation schwere aplastische Anämie)
- LOT-0010Eltrombopag (feste orale DRF: inkl. der Indikation schwere aplastische Anämie)
- LOT-0011Ezetimib/Atorvastatin (88 St., 90 St.)
- LOT-0012Iodid (N3: 0,1 mg, 0,2 mg)
- LOT-0013Nitisinon (feste orale DRF)
- LOT-0014Pazopanib
- LOT-0015Prednison (TAB, ausgenommen 10 mg)